AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Argenx Surges to 453rd in Trading Volume with €207 Million Turnover Amidst Positive CHMP Opinion
Generated by AI AgentAinvest Market Brief
Friday, May 2, 2025 7:45 pm ET1min read
On May 2, 2025,
(ARGX) saw a significant surge in trading volume, with a turnover of €207 million, marking a 77.81% increase from the previous day. This substantial rise placed Argenx at the 453rd position in terms of trading volume for the day. The stock price of Argenx also increased by 1.53%.Argenx recently announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its VYVGART® (efgartigimod alfa) subcutaneous injection. This approval is for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition that has not seen a novel mechanism of action in over three decades. VYVGART® is the first and only targeted IgG Fc-antibody fragment designed for CIDP treatment, representing a significant advancement in the field.
This positive CHMP opinion is a crucial milestone for Argenx, as it recommends the European Commission (EC) for approval of a new treatment for adults with progressive or relapsing active CIDP. This development underscores Argenx's commitment to innovation and its leadership in the biopharmaceutical industry, particularly in the treatment of autoimmune diseases.
Ainvest Market Brief
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Morning Market Pulse: Trump’s Federal Pay Raise & Japan’s Policy Shift Drive Pre-Market Moves
Dec.19 2025
What to Trade Today: Volatility and Inflows Drive Pre-Market Moves
Dec.19 2025
U.S. Corporate Actions | Ticker Changes and Dividend Announcements Highlight Activity
Dec.19 2025
Morning Market Pulse: Trump’s Marijuana Rescheduling and AI Policy Shifts
Dec.18 2025
What to Trade Today: Mixed Macro Signals and Short-Term Glimmers in the Diagonal
Dec.18 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet